Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Waverley Pharma Inc (WAVE) - Total Assets
Latest total assets as of September 2025: CA$1.27 Million CAD
Based on the latest financial reports, Waverley Pharma Inc (WAVE) holds total assets worth CA$1.27 Million CAD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Waverley Pharma Inc - Total Assets Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Waverley Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Waverley Pharma Inc's total assets of CA$1.27 Million consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 11.5% |
| Accounts Receivable | CA$53.06K | 2.6% |
| Inventory | CA$261.49K | 12.8% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$397.94K | 19.5% |
| Goodwill | CA$223.56K | 10.9% |
Asset Composition Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Waverley Pharma Inc's current assets represent 35.7% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 100.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 19.5% of total assets.
Waverley Pharma Inc Competitors by Total Assets
Key competitors of Waverley Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Waverley Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Waverley Pharma Inc generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Waverley Pharma Inc is currently not profitable relative to its asset base.
Waverley Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.13 | 1.53 |
| Quick Ratio | 0.04 | 0.09 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-3.05 Million | CA$ -3.11 Million | CA$ 588.41K |
Waverley Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Waverley Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 114.8% |
| Total Assets | CA$2.05 Million |
| Market Capitalization | $235.88K USD |
Valuation Analysis
Below Book Valuation: The market values Waverley Pharma Inc's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Waverley Pharma Inc's assets grew by 114.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Waverley Pharma Inc (2015–2024)
The table below shows the annual total assets of Waverley Pharma Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$2.05 Million | +114.83% |
| 2023-12-31 | CA$952.29K | -64.56% |
| 2022-12-31 | CA$2.69 Million | -27.05% |
| 2021-12-31 | CA$3.68 Million | +5.50% |
| 2020-12-31 | CA$3.49 Million | -20.53% |
| 2019-12-31 | CA$4.39 Million | -16.10% |
| 2018-12-31 | CA$5.24 Million | -21.35% |
| 2017-12-31 | CA$6.66 Million | +6657768.00% |
| 2016-12-31 | CA$100.00 | 0.00% |
| 2015-12-31 | CA$100.00 | -- |